RUNX1-ETO and RUNX1-EVI1 Differentially Reprogram the Chromatin Landscape in t(8;21) and t(3;21) AML
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Acute myeloid leukemia (AML) is a heterogeneous disease caused by mutations in transcriptional regulator genes, but how different mutant regulators shape the chromatin landscape is unclear. Here, we compared the transcriptional networks of two types of AML with chromosomal translocations of the RUNX1 locus that fuse the RUNX1 DNA-binding domain to different regulators, the t(8;21) expressing RUNX1-ETO and the t(3;21) expressing RUNX1-EVI1. Despite containing the same DNA-binding domain, the two fusion proteins display distinct binding patterns, show differences in gene expression and chromatin landscape, and are dependent on different transcription factors. RUNX1-EVI1 directs a stem cell-like transcriptional network reliant on GATA2, whereas that of RUNX1-ETO-expressing cells is more mature and depends on RUNX1. However, both types of AML are dependent on the continuous expression of the fusion proteins. Our data provide a molecular explanation for the differences in clinical prognosis for these types of AML.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genomic classification and prognosis in acute myeloid leukemia
Papaemmanuil, E., Gerstung, M., Bullinger, L., Gaidzik, V. I., Paschka, P., Roberts, N. D., Potter, N. E., Heuser, M., Thol, F., Bolli, N., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1516192 · Cited by 4,350 · cited 1×
“Subclasses are primarily defined by mutations in transcription factors, epigenetic regulators, and signaling molecules that affect cell growth and transcription factor activity (Cancer Genome Atlas Research Network, 2013; Papaemmanuil et al., 2016).”
A Single Oncogenic Enhancer Rearrangement Causes Concomitant EVI1 and GATA2 Deregulation in Leukemia
Gröschel, S., Sanders, M. A., Hoogenboezem, R., de Wit, E., Bouwman, B. A. M., Erpelinck, C., van der Velden, V. H. J., Havermans, M., Avellino, R., van Lom, K., et al. (2014) · Cell · doi:10.1016/j.cell.2014.02.019 · Cited by 687
Self-citationHoxa9 transforms primary bone marrow cells through specific collaboration with Meis1a but not Pbx1b
Kroon, E., Krosl, J., Thorsteinsdottir, U., Baban, S., Buchberg, A. M., & Sauvageau, G. (1998) · The EMBO Journal · doi:10.1093/emboj/17.13.3714 · Cited by 640
Erickson, P., Gao, J., Chang, K., Look, T., Whisenant, E., Raimondi, S., Lasher, R., Trujillo, J., Rowley, J., & Drabkin, H. (1992) · Blood · doi:10.1182/blood.v80.7.1825.1825 · Cited by 631 · cited 2×
“The most common category of RUNX1 rearrangement is the product of the t(8;21) chromosomal translocation, RUNX1-ETO, which comprises the RUNX1 DNA-binding domain linked to the almost complete ETO protein (also known as RUNX1T1), which functions as a repressor by recruiting histone deacetylases (Bae et al., 1993; Ericks…”
Miyamoto, T., Weissman, I. L., & Akashi, K. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.13.7521 · Cited by 465 · cited 2×
“The t(8;21) translocation is a primarymutation that hits an early stem cell (Miyamoto et al., 2000), whereas t(3;21) is often found in CML patients after blast crisis, indicating that during tumor initiation, the two fusion proteins encounter a dramatically different chromatin landscape that…”
Yergeau, D. A., Hetherington, C. J., Wang, Q., Zhang, P., Sharpe, A. H., Binder, M., Marín-Padilla, M., Tenen, D. G., Speck, N. A., & Zhang, D.-E. (1997) · Nature Genetics · doi:10.1038/ng0397-303 · Cited by 346
Regulation of the PU.1 gene by distal elements
Li, Y., Okuno, Y., Zhang, P., Radomska, H. S., Chen, H.-M., Iwasaki, H., Akashi, K., Klemsz, M. J., McKercher, S. R., Maki, R. A., et al. (2001) · Blood · doi:10.1182/blood.v98.10.2958 · Cited by 110 · cited 2×
“At important myeloid regulator genes, such as Cell Reports 19, 1654–1668, May 23, 2017 1657 the CSF-1 receptor gene (CSF1R) and the PU.1 gene (SPI1), the two fusion proteins target the same regulatory elements (Figures 3A and S3B) (Himes et al., 2001; Li et al., 2001).”
Meyers, S., Downing, J. R., & Hiebert, S. W. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.10.6336-6345.1993 · Cited by 94 · cited 1×
“Although RUNX1-ETO and RUNX1-EVI1 carry the same DNAbinding domain and bind to the same motifs in vitro (Meyers et al., 1993; Tanaka et al., 1995), the two classes of AML have distinct clinical characteristics.”
Cited by
Subtype-specific 3D genome alteration in acute myeloid leukaemia
Xu, J., Song, F., Lyu, H., Kobayashi, M., Zhang, B., Zhao, Z., Hou, Y., Wang, X., Luan, Y., Jia, B., et al. (2022) · Nature · doi:10.1038/s41586-022-05365-x · Cited by 208
Subtype-specific regulatory network rewiring in acute myeloid leukemia
Assi, S. A., Imperato, M. R., Coleman, D. J. L., Pickin, A., Potluri, S., Ptasinska, A., Chin, P. S., Blair, H., Cauchy, P., James, S. R., et al. (2019) · Nature Genetics · doi:10.1038/s41588-018-0270-1 · Cited by 179
Self-citationSubramanian, S., Thoms, J. A. I., Huang, Y., Cornejo-Páramo, P., Koch, F. C., Jacquelin, S., Shen, S., Song, E., Joshi, S., Brownlee, C., et al. (2023) · Blood · doi:10.1182/blood.2023021120 · Cited by 57
“GRNs are significantly perturbed in multiple AML subtypes 75,8 , often as a result of specific translocation events including RUNX1-RUNX1T1 76,77 and inv(3) 65,64 .”
Gain‐of‐Function Effects of N‐Terminal CEBPA Mutations in Acute Myeloid Leukemia
Schmidt, L., Heyes, E., & Grebien, F. (2020) · BioEssays · doi:10.1002/bies.201900178 · Cited by 26
Metadata
- Authors
- Loke, J., Assi, S. A., Imperato, M. R., Ptasinska, A., Cauchy, P., Grabovska, Y., Soria, N. M., Raghavan, M., Delwel, H. R., Cockerill, P. N., Heidenreich, O., & Bonifer, C.
- Venue
- Cell Reports
- Publisher
- Elsevier BV
- Published
- 2017-05
- Volume
- 19
- Issue
- 8
- Pages
- 1654-1668
- ISSN
- 2211-1247 (ISSN-L)
- OpenAlex
- W2619118648
- Cited by
- 56
- References
- 8
- FWCI
- 4.52
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.